Contact | Print version | PDF version | Send article | RSS feed

Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University

Development of a monoclonal antibody for the treatment of Alzheimer’s disease

07 Dec 2009 - Sanofi-aventis announced an exclusive global licensing agreement with The Rockefeller University concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer’s disease.
 
The anti-Amyloid Beta (ABeta) antibody therapy is a highly attractive approach to prevent and reverse the amyloid plaque formation which may lead to cognitive improvement in patients with Alzheimer’s disease. This antibody is planned to enter development at the end of 2009.
 
"It’s a great pleasure to interact with The Rockefeller University and in particular with Dr. Jeffrey Ravetch, a worldwide expert in the engineering of mAb Fc region and effector functions”, declared Marc Cluzel, Executive Vice-President, R&D, sanofi-aventis. "Dr Ravetch discovered the original murine monoclonal antibody targeting the Amyloid Beta peptide, one target which may have a significant positive impact in the management of patients with Alzheimer’s disease, which is a public health priority”.
 
Under the terms of the agreement, sanofi-aventis will obtain an exclusive worldwide license to develop, manufacture and commercialize the anti-ABeta antibody. The terms of such license are undisclosed.